NCT00204633View on ClinicalTrials.gov

"Darbepoetin Alfa in Patients With Poor Prognosis Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP)"

PHASE2CompletedINTERVENTIONAL

Enrollment

108

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

Dysgerminoma

Interventions

DRUG

Darbepoetin alfa

Trial Locations (1)

72076

Medical Center II, University of Tuebingen, Tübingen

All Listed Sponsors

lead

University Hospital Tuebingen

OTHER

NCT00204633 - "Darbepoetin Alfa in Patients With Poor Prognosis Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP)" | Biotech Hunter | Biotech Hunter